Erasca Inc (ERAS) USD0.0001
Erasca, Inc is a clinical-stage precision oncology company. The Company is focused on discovering, developing and commercializing therapies for RAS/MAPK pathway-driven cancers. The Company is engaged in oncology and RAS targeting to create therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of cancer. The Company’s lead product candidates are ERAS-007 and ERAS-601, which together comprise its first MAPKlamp. ERAS-007 is designed to be an oral inhibitor of ERK1/2, which has been evaluated as a single agent in a Phase I clinical trial in patients with advanced solid tumors completed by Asana. ERAS-601 is an oral SHP2 inhibitor, which is under first-in-human Phase I clinical trial, FLAGSHP-1. The Company’s SHP2 inhibitor is designed to block oncogenic signal transduction and delay the onset of therapeutic resistance, which has the potential to serve as a backbone of combination therapy against RAS/MAPK pathway altered cancers.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.